stockportfolio.pro
Merit Medical Systems, Inc. (MMSI)
Healthcare · Medical Instruments & Supplies · NasdaqGS
Merit Medical Systems, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $603.84M | $727.85M | $882.75M | $994.85M | $963.88M | $1.07B | $1.15B | $1.26B | $1.36B | $1.52B |
| Gross profit | $265.02M | $326.25M | $394.77M | $432.37M | $401.18M | $485.33M | $519.10M | $583.87M | $643.33M | $738.27M |
| Net income | $20.12M | $27.52M | $42.02M | $5.45M | $-9.84M | $48.45M | $74.52M | $94.41M | $120.36M | $128.49M |
| Net margin | 3.3% | 3.8% | 4.8% | 0.5% | -1.0% | 4.5% | 6.5% | 7.5% | 8.9% | 8.5% |
Source: Merit Medical Systems, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of Merit Medical Systems, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MMSI in your portfolio →
About Merit Medical Systems, Inc.
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology products, such as soft tissue biopsy products and accessories; cardiac intervention products consisting of cardiac access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention products; and spine products, including vertebral augmentation, radiofrequency ablation, and bone biopsy systems. It also provides custom procedural solutions, including critical care products, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company offers gastroenterology products, such as esophageal stents, cryoballoon and inflation devices, gauges, and balloon dilators; pulmonary products consisting of laser-cut tracheobronchial stents, and over-the-wire and direct visualization delivery systems; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals, alternate site-based physicians, technicians, and nurses through direct sales force, independent distributors, original equipment manufacturer partners, and custom procedure tray manufacturers. The company exports its products to Canada, Western Europe, Australia, Brazil, Malaysia, South Korea, the United Arab Emirates, India, New Zealand, and South Africa. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.
Merit Medical Systems, Inc. — frequently asked questions
What is Merit Medical Systems, Inc.'s revenue?
Merit Medical Systems, Inc. (MMSI) reported revenue of $1.52B for fiscal year 2025, up 11.8% from the prior year, according to its SEC filings.
Is Merit Medical Systems, Inc. profitable?
Yes. MMSI earned net income of $128.49M in fiscal 2025, a net margin of 8.5%.
What is MMSI's P/E ratio?
Merit Medical Systems, Inc. trades at a price-to-earnings ratio of about 28.8 based on the latest data in our nightly-refreshed cache.
How fast is Merit Medical Systems, Inc. growing?
MMSI's revenue grew at roughly 9.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Merit Medical Systems, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.